Evolus (EOLS)
(Delayed Data from NSDQ)
$11.50 USD
-0.20 (-1.71%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $11.48 -0.02 (-0.17%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.50 USD
-0.20 (-1.71%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $11.48 -0.02 (-0.17%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
Schrodinger (SDGR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Schrodinger's (SDGR) first-quarter results are likely to reflect benefits from collaborations.
Why Evolus (EOLS) Might Surprise This Earnings Season
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Asensus Surgical's (ASXC) Q1 Earnings?
by Zacks Equity Research
Asensus Surgical's (ASXC) first-quarter results are likely to reflect benefits from regulatory approvals and collaboration.
Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Science Applications (SAIC) 4Q Earnings?
by Zacks Equity Research
Science Applications' (SAIC) fourth-quarter fiscal 2021 performance is likely to reflect benefits from new contract wins and acquisitions of Engility and Unisys Federal acquisition.
CuriosityStream (CURI) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
CuriosityStream's (CURI) fourth-quarter 2020 results are expected to reflect expanding subscriber base, driven by strong factual content portfolio.
Is a Surprise Coming for Evolus (EOLS) This Earnings Season?
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Do Options Traders Know Something About Evolus (EOLS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Evolus (EOLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Why Earnings Season Could Be Great for Evolus (EOLS)
by Zacks Equity Research
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Implied Volatility Surging for Evolus (EOLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
What's in Store for Flexible Solutions (FSI) in Q2 Earnings?
by Zacks Equity Research
Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.